After SP600125 treatment, the CDK2 mRNA expression level in the OE-KLF14+S group was lower than its control group (all P<0.001) (Figures 7A, B), indicating that inhibition of JNK-pathway activation reversed KLF14-induced CDK2 mRNA expression in cervical cancer cells. The gene discussed is CDK2; the disease is cervical cancer.